Fig. 2
From: Bevacizumab treatment of meningeal melanoma metastases
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12967-020-02212-3/MediaObjects/12967_2020_2212_Fig2_HTML.png)
Microvascular density and angiogenic activity. a CD31-stained histological preparations of untreated and bevacizumab-treated meningeal A-07 and D-12 tumors illustrating that the tumors were vascularized by abnormal vessels. b Microvascular density (MVD) and angiogenic activity in untreated and bevacizumab-treated meningeal A-07 and D-12 tumors. Bevacizumab treatment did not reduce MVD in any of the models, whereas angiogenic activity was reduced in bevacizumab-treated A-07 tumors but not in bevacizumab-treated D-12 tumors. Columns: mean of 5 tumors. Bars: standard error. P-values: one-sided t-test